109 related articles for article (PubMed ID: 19620877)
1. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
Boffito M; Jackson A; Lamorde M; Back D; Watson V; Taylor J; Waters L; Asboe D; Gazzard B; Pozniak A
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):222-7. PubMed ID: 19620877
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.
Di Perri G; Green B; Morrish G; Hill A; Faetkenheuer G; Bickel M; van Delft Y; Kurowski M; Kakuda T
HIV Clin Trials; 2013; 14(3):92-8. PubMed ID: 23835511
[TBL] [Abstract][Full Text] [Related]
4. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
[TBL] [Abstract][Full Text] [Related]
5. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
Kakuda TN; Leopold L; Nijs S; Vandevoorde A; Crauwels HM; Bertelsen KM; Stevens M; Witek J; van Delft Y; Tomaka F; Hoetelmans RM
J Clin Pharmacol; 2014 May; 54(5):563-73. PubMed ID: 25975423
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
[TBL] [Abstract][Full Text] [Related]
9. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Fätkenheuer G; Duvivier C; Rieger A; Durant J; Rey D; Schmidt W; Hill A; van Delft Y; Marks S;
J Antimicrob Chemother; 2012 Mar; 67(3):685-90. PubMed ID: 22210755
[TBL] [Abstract][Full Text] [Related]
10. Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
Gutiérrez-Valencia A; Martin-Peña R; Torres-Cornejo A; Ruiz-Valderas R; Castillo-Ferrando JR; López-Cortés LF
J Antimicrob Chemother; 2012 Mar; 67(3):681-4. PubMed ID: 22190606
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069
[TBL] [Abstract][Full Text] [Related]
13. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
[TBL] [Abstract][Full Text] [Related]
14. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
[TBL] [Abstract][Full Text] [Related]
15. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
Sekar VJ; De Pauw M; Mariën K; Peeters M; Lefebvre E; Hoetelmans RM
Antivir Ther; 2007; 12(4):509-14. PubMed ID: 17668559
[TBL] [Abstract][Full Text] [Related]
17. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
[TBL] [Abstract][Full Text] [Related]
19. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
